Vitamin B6 supplementation in quadruple H. pylori treatment: Mitigating adverse reactions

Summaries 3 min 1450

Font Size

Created On: 19/12/2023

This trial was conducted to assess the potential of Vitamin B6 in alleviating the side effects induced by the quadruple anti-Helicobacter pylori (H. pylori) therapeutic regimen, which includes Minocycline and Metronidazole.

See All

Key take away

Inclusion of Vitamin B6 in the quadruple anti-H. pylori regimen, with Minocycline and Metronidazole, can ameliorate adverse reactions.

Background

Method

In this randomized controlled trial, a total of 280 individuals diagnosed with H. pylori infection were randomized to either the standard treatment group or the group receiving Vitamin B6 supplements for a duration of two weeks. The major outcome measured was the overall occurrence of adverse reactions within two weeks of commencing treatment. The study adhered to the CONSORT Medicinal Interventions guidelines.

Result

Vitamin B6 displayed no impact on the effectiveness of the standard therapeutic regimen. Notably, in the group receiving Vitamin B6 supplements, the occurrence of adverse reactions amounted to 56.92%, substantially reduced than the 74.62% observed in the standard treatment group. Furthermore, the severity of these reactions markedly decreased.

The percentage of moderate to severe central nervous system symptoms dropped from 58.7% to 14.63%. On the other hand, moderate to severe gastrointestinal reactions dropped from 33.33% to 0%. The hypothesis suggests that the mechanism through which Vitamin B6 reduces adverse reactions may be linked to its role in gamma-aminobutyric acid (GABA) production within the brain.